在淋病中空纤维感染模型中评估头孢曲松单剂治疗(0.125-1 g)清除头孢曲松敏感和耐药淋病奈瑟菌的药效学
在中空纤维感染模型中模拟头孢曲松0.125-1 g单剂肌注方案,评估对敏感和耐药淋病奈瑟菌株的药效。结果显示0.5 g和1 g可清除多数低水平耐药株,但0.5 g未能清除高水平耐药株WHO X,模拟口咽感染时1 g仅清除WHO R和Z。作者建议将头孢曲松1 g(±阿奇霉素2 g)作为一线经验性治疗。
要点
- 头孢曲松0.125-1 g单剂快速清除头孢曲松敏感株WHO F。
- 头孢曲松1 g可清除低水平耐药株WHO R和Z,但未能清除高水平耐药株WHO X。
- 作者建议头孢曲松1 g(±阿奇霉素2 g)作为一线经验性淋病治疗。
核心结论
- 头孢曲松1 g单剂肌注可治愈多数由当前国际传播的头孢曲松耐药淋病奈瑟菌株引起的肛门生殖器和口咽淋病,该结果应进一步在临床上确认。
- 作者建议将头孢曲松1 g(±阿奇霉素2 g)作为一线经验性淋病治疗,这可为国家在新型抗菌药物获批前争取时间。
- 使用头孢曲松1 g治疗淋病时,EUCAST头孢曲松耐药折点过低。
研究设计与样本
- 采用淋病中空纤维感染模型(HFIM)进行为期7天的剂量范围实验,模拟头孢曲松0.125-1 g单剂肌注方案。
- 受试菌株为WHO F(头孢曲松敏感,MIC < 0.002 mg/L)、WHO R(耐药,MIC = 0.5 mg/L)、WHO Z(耐药,MIC = 0.5 mg/L)和WHO X(耐药,MIC = 2 mg/L)。
- 耐药判定基于EUCAST头孢曲松耐药折点(MIC > 0.125 mg/L)。
主要发现
- 头孢曲松0.125-1 g单剂治疗快速清除了WHO F(野生型头孢曲松MIC)。
- 基于头孢曲松人体血浆药代动力学参数,头孢曲松0.5 g和1 g清除了多数头孢曲松耐药淋病奈瑟菌株(WHO R和Z),但头孢曲松0.5 g未能清除WHO X(高水平头孢曲松耐药)。
- 模拟口咽淋病时,头孢曲松0.5 g未能清除所有头孢曲松耐药株;头孢曲松1 g清除了WHO R和Z(低水平头孢曲松耐药),但未能清除WHO X(高水平头孢曲松耐药)。
- 任何头孢曲松治疗均未筛选出头孢曲松耐药突变株。
关键数值与推荐
- EUCAST头孢曲松耐药折点为MIC > 0.125 mg/L。
- WHO F的头孢曲松MIC < 0.002 mg/L;WHO R和Z的MIC = 0.5 mg/L;WHO X的MIC = 2 mg/L。
临床怎么用
- 作者建议将头孢曲松1 g(±阿奇霉素2 g)作为一线经验性淋病治疗。
- 作者认为使用头孢曲松1 g治疗淋病时,EUCAST头孢曲松耐药折点过低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antimicrobial resistance in Neisseria gonorrhoeae is threatening the gonorrhoea treatment, and optimizations of the current ceftriaxone-treatment regimens are crucial. We evaluated the pharmacodynamics of ceftriaxone single-dose therapy (0.125-1 g) against ceftriaxone-susceptible and ceftriaxone-resistant gonococcal strains, based on EUCAST ceftriaxone-resistance breakpoint (MIC > 0.125 mg/L), in our hollow fibre infection model (HFIM) for gonorrhoea. METHODS: Gonococcal strains examined were WHO F (ceftriaxone-susceptible, MIC < 0.002 mg/L), R (ceftriaxone-resistant, MIC = 0.5 mg/L), Z (ceftriaxone-resistant, MIC = 0.5 mg/L) and X (ceftriaxone-resistant, MIC = 2 mg/L). Dose-range HFIM 7 day experiments simulating ceftriaxone 0.125-1 g single-dose intramuscular regimens were conducted. RESULTS: Ceftriaxone 0.125-1 g single-dose treatments rapidly eradicated WHO F (wild-type ceftriaxone MIC). Ceftriaxone 0.5 and 1 g treatments, based on ceftriaxone human plasma pharmacokinetic parameters, eradicated most ceftriaxone-resistant gonococcal strains (WHO R and Z), but ceftriaxone 0.5 g failed to eradicate WHO X (high-level ceftriaxone resistance). When simulating oropharyngeal gonorrhoea, ceftriaxone 0.5 g failed to eradicate all the ceftriaxone-resistant strains, while ceftriaxone 1 g eradicated WHO R and Z (low-level ceftriaxone resistance) but failed to eradicate WHO X (high-level ceftriaxone resistance). No ceftriaxone-resistant mutants were selected using any ceftriaxone treatments. CONCLUSIONS: Ceftriaxone 1 g single-dose intramuscularly cure most of the anogenital and oropharyngeal gonorrhoea cases caused by the currently internationally spreading ceftriaxone-resistant gonococcal strains, which should be further confirmed clinically. A ceftriaxone 1 g dose (±azithromycin 2 g) should be recommended for first-line empiric gonorrhoea treatment. This will buy countries some time until novel antimicrobials are licensed. Using ceftriaxone 1 g gonorrhoea treatment, the EUCAST ceftriaxone-resistance breakpoint is too low.
引用
- Unemo M, Golparian D, Oxelbark J, et al. Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea. J Antimicrob Chemother. 2024. PMID: 38497988. doi:10.1093/jac/dkae063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。